Stoke Therapeutics, Inc. (STOK)
32.29
-0.99
(-2.97%)
USD |
NASDAQ |
May 07, 14:14
Stoke Therapeutics Cash from Investing (Quarterly) : -61.06M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Krystal Biotech, Inc. | -63.58M |
| Scholar Rock Holding Corp. | 38.97M |
| Vertex Pharmaceuticals, Inc. | -431.90M |
| Zymeworks, Inc. | 5.097M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -30.45M |
| Cash from Financing (Quarterly) | 92.34M |
| Free Cash Flow | 44.92M |
| Free Cash Flow Per Share (Quarterly) | -0.5255 |
| Free Cash Flow to Equity (Quarterly) | -30.05M |
| Free Cash Flow to Firm (Quarterly) | -30.68M |
| Free Cash Flow Yield | 2.37% |